scholarly journals Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters

Theranostics ◽  
2016 ◽  
Vol 6 (12) ◽  
pp. 2084-2098 ◽  
Author(s):  
Xiao Bao ◽  
Ming-Wei Wang ◽  
Jian-Min Luo ◽  
Si-Yang Wang ◽  
Yong-Ping Zhang ◽  
...  
2014 ◽  
Vol 41 (8) ◽  
pp. 1553-1562 ◽  
Author(s):  
Byung Hyun Byun ◽  
Chang-Bae Kong ◽  
Ilhan Lim ◽  
Byung Il Kim ◽  
Chang Woon Choi ◽  
...  

Molecules ◽  
2017 ◽  
Vol 22 (11) ◽  
pp. 1946 ◽  
Author(s):  
Yi-Hsiu Chung ◽  
Cheng-Kun Tsai ◽  
Chiun-Chieh Wang ◽  
Hsi-Mu Chen ◽  
Kuan-Ying Lu ◽  
...  

2020 ◽  
Vol 6 (40) ◽  
pp. eabc2777 ◽  
Author(s):  
Anh Nguyen ◽  
Anujan Ramesh ◽  
Sahana Kumar ◽  
Dipika Nandi ◽  
Anthony Brouillard ◽  
...  

Despite recent advancements in cancer immunotherapy, accurate monitoring of its efficacy is challenging due to heterogeneous immune responses. Conventional imaging techniques lack the sensitivity and specificity for early response assessment. In this study, we designed a granzyme B (GrB) nanoreporter (GNR) that can deliver an immune checkpoint inhibitor to the tumor and track time-sensitive GrB activity as a direct way to monitor initiation of effective immune responses. Anti–programmed death-ligand 1 (PD-L1) antibody–conjugated GNRs inhibited PD-1/PD-L1 interactions efficiently and induced T cell–mediated GrB release that can be imaged using activatable imaging probe. GNRs enabled real-time immunotherapy response monitoring in a tumor-bearing mice model and distinguished between highly responsive and poorly responsive tumors. Furthermore, increasing doses resulted in a better response and enhanced sensitivity in poorly responsive tumors. These findings indicate that GNR has the potential to serve as a tool for sensitive and noninvasive evaluation of immunotherapy efficacy.


2020 ◽  
Vol 20 (30) ◽  
pp. 2737-2761
Author(s):  
Ke-Tao Jin ◽  
Jia-Yu Yao ◽  
Xiao-Jiang Ying ◽  
Yan Lin ◽  
Yun-Fang Chen

Incorporating nanotechnology into fluorescent imaging and magnetic resonance imaging (MRI) has shown promising potential for accurate diagnosis of cancer at an earlier stage than the conventional imaging modalities. Molecular imaging (MI) aims to quantitatively characterize, visualize, and measure the biological processes or living cells at molecular and genetic levels. MI modalities have been exploited in different applications including noninvasive determination and visualization of diseased tissues, cell trafficking visualization, early detection, treatment response monitoring, and in vivo visualization of living cells. High-affinity molecular probe and imaging modality to detect the probe are the two main requirements of MI. Recent advances in nanotechnology and allied modalities have facilitated the use of nanoparticles (NPs) as MI probes. Within the extensive group of NPs, fluorescent NPs play a prominent role in optical molecular imaging. The fluorescent NPs used in molecular and cellular imaging can be categorized into three main groups including quantum dots (QDs), upconversion, and dyedoped NPs. Fluorescent NPs have great potential in targeted theranostics including cancer imaging, immunoassay- based cells, proteins and bacteria detections, imaging-guided surgery, and therapy. Fluorescent NPs have shown promising potentials for drug and gene delivery, detection of the chromosomal abnormalities, labeling of DNA, and visualizing DNA replication dynamics. Multifunctional NPs have been successfully used in a single theranostic modality integrating diagnosis and therapy. The unique characteristics of multifunctional NPs make them potential theranostic agents that can be utilized concurrently for diagnosis and therapy. This review provides the state of the art of the applications of nanotechnologies in early cancer diagnosis focusing on fluorescent NPs, their synthesis methods, and perspectives in clinical theranostics.


Sign in / Sign up

Export Citation Format

Share Document